What this record means
The record shows that RYZEGLA is an abandoned application, filed by ACADIA Pharmaceuticals Inc. on May 8 2017 and listed on the Principal Register, but the USPTO issued an abandonment notice on December 14 2020 because no Statement of Use was filed after the Notice of Allowance. The only goods covered are “pharmaceutical preparations for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders” in International Class 5, so a later user of a similar name in that therapeutic space would encounter the closest record‑based concern. The record does not give ACADIA control over every use of the word RYZEGLA in other industries or contexts. No Supplemental Register action appears, and the latest meaningful event is the abandonment notice on December 14 2020; no further dates are listed. The prosecution history contains no oppositions, cancellations or court actions, so the supplied history shows no visible enforcement activity. I'd treat this as a moderate concern if you plan a pharma‑related brand that overlaps the same therapeutic categories.
Informational only - not legal advice.